SCHEMBL3094764

SCHEMBL3094764

N#CC(C#N)=C(O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.52
ALDH1A1 P00352 7/20 0.52
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 3/20 0.41
TSHR P16473 4/20 0.40
MAPT P10636 3/20 0.40
RECQL P46063 2/20 0.40
CYP2C19 P33261 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
CYP3A4 P08684 1/20 0.40
PARP1 P09874 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAPK1 P28482 2/20 0.38
RAB9A P51151 2/20 0.38
LMNA P02545 1/20 0.38
XBP1 P17861 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9791325 0.89 EGFR (0.56) EGFRALDH1A1KMT2AMEN1POLB
SCHEMBL10593807 0.86 ALDH1A1 (0.46) EGFRALDH1A1KMT2AMEN1POLB
SCHEMBL9791338 0.85 EGFR (0.54) EGFRALDH1A1KMT2AMEN1POLB
SCHEMBL202753 0.81 PARP10 (0.53) EGFRTSHR
SCHEMBL8743684 0.80 EGFR (0.54) EGFRALDH1A1KMT2AMEN1TSHR
SCHEMBL134312 0.79 ALDH1A1 (0.52) EGFRALDH1A1KMT2AMEN1POLB
SCHEMBL16886108 0.78 EGFR (0.47) EGFRALDH1A1KMT2AMEN1POLB
SCHEMBL726503 0.78 EGFR (0.47) EGFRALDH1A1KMT2AMEN1TSHR
SCHEMBL14698829 0.78 EGFR (0.47) EGFRALDH1A1KMT2AMEN1MAPT
SCHEMBL15669600 0.78 EGFR (0.47) EGFRALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3553097-B1 COPOLYMER AND OPTICAL FILM USING SAME TOSOH CORP (JP) 2022-05-04 EP disclosed
US-11225540-B2 Copolymer and optical film using same TOSOH CORPORATION (JP) 2022-01-18 US disclosed
CN-110248971-B Copolymer and optical film using the same 东曹株式会社 2021-11-02 CN disclosed
US-20210002251-A1 Bruton's Tyrosine Kinase Inhibitors PFIZER INC. (US) 2021-01-07 US disclosed
US-10815213-B2 Bruton's tyrosine kinase inhibitors PFIZER INC. (US) 2020-10-27 US disclosed
US-20200095358-A1 COPOLYMER AND OPTICAL FILM USING SAME TOSOH CORPORATION (JP) 2020-03-26 US disclosed
EP-3553097-A1 COPOLYMER AND OPTICAL FILM USING SAME Tosoh Corporation (JP) 2019-10-16 EP disclosed
US-20190202798-A1 Bruton's Tyrosine Kinase Inhibitors PFIZER INC. (US) 2019-07-04 US disclosed
US-10266513-B2 Bruton's tyrosine kinase inhibitors PFIZER INC. (US) 2019-04-23 US disclosed
US-20170283393-A1 Bruton's Tyrosine Kinase Inhibitors PFIZER INC. (US) 2017-10-05 US disclosed
US-20150291554-A1 Bruton's Tyrosine Kinase Inhibitors PFIZER (US) 2015-10-15 US disclosed
WO-2014068527-A1 BRUTON'S TYROSINE KINASE INHIBITORS PFIZER INC. (US) 2014-05-08 WO disclosed
EP-1661897-B1 PYRROLOPYRIMIDINONE DERIVATIVE TEIJIN PHARMA LTD (JP) 2013-12-04 EP disclosed
US-8536205-B2 Photochromic and electrochromic compounds and synthesis and use thereof SWITCH MATERIALS INC. (CA) 2013-09-17 US disclosed
US-20100190868-A1 PHOTOCHROMIC AND ELECTROCHROMIC COMPOUNDS AND SYNTHESIS AND USE THEREOF SWITCH MATERIALS INC. (CA) 2010-07-29 US disclosed
US-7557113-B2 Substituted pyrrolo[3,2-d]pyrimidine derivatives TEIJIN PHARMA LIMITED (JP) 2009-07-07 US disclosed
US-20060160831-A1 Pyrrolopyrimidinone derivatives TEIJIN PHARMA LIMITED (JP) 2006-07-20 US disclosed
EP-1661896-A1 PYRROLOPYRIMIDINETHIONE DERIVATIVE Teijin Pharma Limited (JP) 2006-05-31 EP disclosed
EP-1661897-A1 PYRROLOPYRIMIDINONE DERIVATIVE Teijin Pharma Limited (JP) 2006-05-31 EP disclosed
US-20050153992-A1 Pyrrolopyrimidine thion derivatives TEIJIN PHARMA LIMITED (JP) 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266513-B2 Bruton's tyrosine kinase inhibitors BTK, LCK, LYN EGFR 856/4885ALDH1A1 4293/4885KMT2A 1448/4885
US-20150291554-A1 Bruton's Tyrosine Kinase Inhibitors BTK, LCK, LYN EGFR 833/4885ALDH1A1 4570/4885KMT2A 1497/4885
US-20050153992-A1 Pyrrolopyrimidine thion derivatives GSK3B, GSK3A, GSKIP EGFR 688/4885ALDH1A1 2955/4885KMT2A 1753/4885
US-10815213-B2 Bruton's tyrosine kinase inhibitors BTK, LCK, LYN EGFR 653/4885ALDH1A1 4142/4885KMT2A 1780/4885
US-20210002251-A1 Bruton's Tyrosine Kinase Inhibitors BTK, LCK, LYN EGFR 653/4885ALDH1A1 4142/4885KMT2A 1780/4885
US-20100190868-A1 PHOTOCHROMIC AND ELECTROCHROMIC COMPOUNDS AND SYNTHESIS AND USE THEREOF HCN2, HCN1, SCO2 EGFR 3013/4885ALDH1A1 488/4885KMT2A 3507/4885
US-20170283393-A1 Bruton's Tyrosine Kinase Inhibitors BTK, LCK, LYN EGFR 856/4885ALDH1A1 4293/4885KMT2A 1448/4885
US-20060160831-A1 Pyrrolopyrimidinone derivatives GSK3B, GSK3A, GSKIP EGFR 804/4885ALDH1A1 2940/4885KMT2A 1602/4885
US-20190202798-A1 Bruton's Tyrosine Kinase Inhibitors BTK, LCK, SYK EGFR 712/4885ALDH1A1 4090/4885KMT2A 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.